Inhibitory effects of osemozotan, a serotonin lA-receptor agonist, on methamphetamine-induced c-fos expression in prefrontal cortical neurons

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 4, 2009, Pages 728-731

  Tsuchida, Rie ^a   Kubo, Masahiro ^a   Shintani, Norihito ^a   Abe, Michikazu ^c   Köves, Katalin ^d   Uetsuki, Kazuki ^a   Kuroda, Mariko ^a   Hashimoto, Hitoshi ^a,b   Baba, Akemichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

C fos; Medialprefrontalcortex; Osemozotan; Psychostimulant; Serotonin 5 ht1a receptor; Striatum

Indexed keywords

METHAMPHETAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OSEMOZOTAN; PROTEIN C FOS; SEROTONIN 1A RECEPTOR;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN NERVE CELL; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; INJECTION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROTEIN EXPRESSION;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DIOXANES; DIOXOLES; GENE EXPRESSION; GENES, FOS; IMMUNOHISTOCHEMISTRY; MALE; METHAMPHETAMINE; MICE; MICE, INBRED ICR; NEOSTRIATUM; NEURONS; PIPERAZINES; PREFRONTAL CORTEX; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 65249175686     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.728     Document Type: Article

References (18)

1. Solanto M. V, Behav. Brain Res., 130, 65-71 (2002).
2. Wilens T. E., Biederman J., Spencer T. J., Annu. Rev. Med., 53, 113 - 131 (2002).
3. Andersen S. L., Trends Pharmacol. Sci., 26, 237-243 (2005).
4. Gainetdinov R. R., Wetsel W. C., Jones S. R., Levin E. D., Jaber M., Caron M. G., Science, 283, 397-401 (1999).
5. Vaudry D., Gonzalez B. J., Basille M., Yon L., Fournier A., Vaudry H., Pharmacol. Rev., 52, 269-324 (2000).
6. Hashimoto H., Shintani N., Tanaka K., Mori W., Hirose M., Matsuda T., Sakaue M., Miyazaki J., Niwa H., Tashiro F., Yamamoto K., Koga K., Tomimoto S., Kunugi A., Suetake S., Baba A., Proc. Natl. Acad. Sci. U.S.A., 98, 13355-13360 (2001).
7. Tanaka K., Shintani N., Hashimoto H., Kawagishi N., Ago Y., Matsuda T., Hashimoto R., Kunugi H., Yamamoto A., Kawaguchi C., Shimada T., Baba A., J. Neurosci., 26, 5091-5097 (2006).
8. Tomimoto S., Ojika T., Shintani N., Hashimoto H., Hamagami K., Ikeda K., Nakata M., Yada T., Sakurai Y., Shimada T., Morita Y., Ishida C., Baba A., J. Pharmacol. Sci., 107, 41-48 (2008).
9. Goldman-Rakic P. S., Muly E. C. 3rd, Williams G. V., Brain Res. Brain Res. Rev., 31, 295-301 (2000).
10. Matsuda T., Yoshikawa T., Suzuki M., Asano S., Somboonthum P., Takuma K., Nakano Y., Morita T., Nakasu Y., Kim H. S., Jpn. J. Pharmacol., 69, 357-366 (1995).
11. Abe M., Tabata R., Saito K., Matsuda T., Baba A., Egawa M., J. Pharmacol. Exp. Ther., 278, 898-905 (1996).
12. Franklin K. B. J., Paxinos G., "The Mouse Brain in Stereotaxic Coordinates," Academic Press, San Diego, 1997.
13. Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F., Cereb. Cortex, 14, 1100-1109 (2004).
14. Badiani A., Oates M. M., Day H. E., Watson S. J., Akil H., Robinson T. E., J Neurosci., 18, 10579-10593 (1998).
15. Przegalinski E., Filip M., Behav. Pharmacol., 8, 699-706 (1997).
16. Przegalinski E., Siwanowicz J., Baran L., Filip M., Life Sci., 66, 1011-1019 (2000).
17. Ago Y., Nakamura S., Uda M., Kajii Y., Abe M., Baba A., Matsuda T., Neuropharmacology, 51, 914-922 (2006).
18. Ago Y., Nakamura S., Baba A., Matsuda T., J. Pharmacol. Sci., 106, 15-21 (2008).